HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Brincidofovir

HCID 483477
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
444805-28-1
Standard SMILES
CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O
InChIKey
WXJFKKQWPMNTIM-VWLOTQADSA-N
Molecular formula
C27H52N3O7P
Average molar mass
561.7 g/mol
Monoisotopic mass
561.354288

Overview

Brincidofovir is a hydroxypyrimidine.

Names & identifiers

Preferred name
Brincidofovir
IUPAC
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
English name
CMX 001
Molecular formula
C27H52N3O7P
Molecular weight
561.69

Names & synonyms

Brincidofovir444805-28-1CMX001HDP-CidofovirHexadecyloxypropyl-cidofovirCMX-001HDP-CDVHexadecyloxypropyl cidofovirTembexaCMX 001[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acidCidofovir Hexadecyloxypropyl Ester
Show more names
Brincidofovir (CMX001)CS-2275HDP-HPMPCCMX 001 - Bio-X ?CMX001(Brincidofovir)Fampridine Impurity 23
6794O900AX1-O-hexadecylpropanediol-CDVDTXSID60196190Phosphonic acid, p-(((1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, mono(3-(hexadecyloxy)propyl) esterbrincidofovirum((2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl)oxymethyl-(3-hexadecoxypropoxy)phosphinic acidRefChem:57400DTXCID70118681

Database identifiers

CAS
444805-28-1
PubChem CID
483477
DTXSID

Properties

Computed structural properties

XLogP
4.9
Topological polar surface area
144 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
7
Rotatable bonds
26
Heavy atoms
38
Formal charge
0
Complexity
721

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
SolubilityPractically insoluble
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
177 ° · > 177° C (dec.)
Boiling point
688.6 · 688.6±65.0 °C(Predicted)
Density
1.17 · 1.17±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility
DMSO (Slightly, Sonicated), Ethanol (Slightly, Heated, Sonicated), Methanol (Sli
form
Solid
pka
2.4 · 2.40±0.10(Predicted)
color
White to Off-White

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Hepatotoxicity · 1 item

In preregistration clinical trials of brincidofovir as prevention of cytomegalovirus and adenovirus infection in adults and children after hematopoietic stem cell transplantation (HSCT), serum aminotransferase elevations were more frequent with brincidofovir (22%) than placebo (16%) treatment, the usual rate of hepatic enzyme elevations being high after HSCT. ALT elevations above 5 times the upper limit of normal (ULN) arose in 1.8% vs 1.4% , and one of 269 brincidofovir recipients discontinued therapy because of ALT elevations above 10 times ULN. The ALT and AST elevations arose early as brincidofovir was given only 2 or 3 times, on days 1 and 8 and in some trials day 21 of treatment. In the same trials mild-to-moderate elevations in serum bilirubin arose in 6.5% of those on brincidofovir vs 5.9% of placebo recipients, again reflecting the high rate of bilirubin elevations in patients after HSCT. In small studies in healthy human volunteers abnormalities of liver tests were not observed. Since approval of brincidofovir, there have been no instances of smallpox infection that qualified for its use. However, the emergence of mpox infection shortly after its approval has led to its use for this non-approved indication. Aminotransferase elevations were frequent in the mpox virus infected subjects treated with brincidofovir but were invariably asymptomatic, transient and without symptoms or concurrent bilirubin elevations. Thus, the total clinical experience with use of brincidofovir is limited. While transient serum aminotransferase elevations have been reported with its use, there have been no reports of clinically apparent liver injury linked to brincidofovir therapy.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
WGK 3
Signal word
Danger
Symbol(GHS)
GHS06,GHS08
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Chemistry & industry

Pharmacology

ATC Code · 2 items

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingBrincidofovir is >99% protein-bound in plasma, although the specific protein(s) to which it binds have not been elucidated.
Pharmacodynamics · 1 item

The pharmacologically active agent resulting from brincidofovir metabolism, cidofovir diphosphate, has an exceedingly long duration of action that allows for it to be dosed once weekly. The entirety of a brincidofovir smallpox treatment consists of only two doses, on days 1 and 8, which seemingly reduces the risk of adverse reactions. Regimens involving a longer duration of administration (i.e. more than a single dose on days 1 and 8) have been shown to increase mortality compared to placebo and should therefore be avoided. Brincidofovir is considered a potential human carcinogen and has demonstrated the potential to cause infertility - as such, its use should be restricted to situations in which it is absolutely necessary.

Mechanism of Action · 1 item

Brincidofovir is a pro-drug comprising [cidofovir] conjugated to a lipid molecule - the lipid component mimics an endogenous lipid, lysophosphatidylcholine, which allows the molecule to hijack endogenous lipid uptake pathways to enter infected cells. Following uptake, the lipid molecule is cleaved to generate cidofovir, which is then phosphorylated to generate the active antiviral compound, cidofovir disphosphate. The antiviral effects of cidofovir diphosphate appear to be the result of two distinct mechanisms. Mechanistic studies using recombinant vaccinia DNA polymerase suggest that it inhibits orthopoxvirus DNA polymerase-mediated DNA synthesis. In addition, cidofovir is an acyclic nucleotide analogue of deoxycytidine monophosphate - cidofovir diphosphate can therefore be incorporated into the growing viral DNA chain and consequently slow the rate of viral DNA synthesis.

Biological Half-LifeThe mean terminal half-lives of brincidofovir and its pharmacologically active metabolite, cidofovir diphosphate, are 19.3 hours and 113 hours, respectively.

Related reactions

2 records
New reaction record
HRID 624683 reaction equation
HRID 624683As product
HRID 1046038 reaction equation
HRID 1046038As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID60196190
ChEMBL
CHEMBL203321
ChEBI
CHEBI:231032
UNII
6794O900AX
Nikkaji
J2.075.976C
Stability
Hygroscopic
InChIKey
WXJFKKQWPMNTIM-VWLOTQADSA-N
SMILES
P(CO[C@H](CO)CN1C(=O)N=C(N)C=C1)(=O)(O)OCCCOCCCCCCCCCCCCCCCC
FDA UNII
6794 O900AX · 6794O900AX
NCI Drug Dictionary
brincidofovir
Comptox DTXSID
60196190 · DTXSID60196190
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06,GHS08
Signal word
Danger
Hazard statements
301 · H301-H317-H351-H361d
Precautionary statements
202 · P202-P261-P264-P280-P301+P310-P302+P352
WGK Germany
3 · WGK 3
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralCarc · Acute Tox. 3 OralCarc. 2Repr. 2Skin Sens. 1
Hazard statements
H301-H317-H351-H361d
Hazard Classifications
Acute Tox. 3 OralCarc. 2Repr. 2Skin Sens. 1
Precautionary statements
P202-P261-P264-P280-P301+P310-P302+P352
Metabolism/Metabolites · 1 item

Brincidofovir is a pro-drug of [cidofovir] and as such must undergo some basic metabolic reactions to become pharmacologically active. Upon entering the target cell, the phosphodiester bond of brincidofovir is hydrolyzed to generate cidofovir, which is then phosphorylated to generate the active agent: cidofovir diphosphate. The specific enzyme(s) responsible for this reaction have not been elucidated, but _in vitro_ findings suggest sphingomyelin phosphodiesterase plays a major role in the initial hydrolysis of brincidofovir. There are two major inactive metabolites of brincidofovir, CMX103 and CMX064, which are generated via carboxylation of the terminal carbon followed by several cycles of CYP-mediated oxidative reactions and fatty acid oxidation. These reactions are mediated, at least in part, by CYP4F2.

MeSH Pharmacological Classification · 1 item

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Absorption, Distribution and Excretion · 4 items

The oral bioavailability of brincidofovir is 13.4% in its tablet formulation and 16.8% in its suspension formulation. Following oral administration, the Cmax and AUCtau of brincidofovir were 480 ng/mL and 3400 ng·hr/mL, respectively. The Cmax and AUCtau of the active metabolite, cidofovir diphosphate, were 9.7 pg/106 cells and 1200 pg·hr/106 cells, respectively. Maximum plasma concentrations (Tmax) of brincidofovir are reached at approximately 3 hours post-administration, while maximal plasma concentrations for cidofovir diphosphate are reached at approximately 47 hours post-administration.

Brincidofovir is eliminated as metabolites in both the urine (~51%) and feces (~40%).

The apparent volume of distribution of brincidofovir is 1230 L.

The apparent clearance of brincidofovir in healthy adult patients is 44.1 L/h.

Applications

UsesBrincidofovir is an antiviral inhibitor, working against BK polymavirus replication in primary human urothelial cells. Cytostatic, cytotoxic agent.